论文部分内容阅读
牙周炎是成人牙齿丧失的首要原因,以牙周组织的炎症和牙槽骨的吸收为主要临床表现。现今治疗牙周炎的药物主要是硝基咪唑类、青霉素类和四环素类,用于控制菌斑、消除炎症;但缺乏能够改建牙槽骨、促进牙槽骨再生的药物,因此影响了临床疗效。寻找促进成骨的药物尤为重要,通过查阅文献,很多研究表明辛伐他汀、贝尼地平、柚皮苷和蛇床子素具有成骨作用,能够修复牙槽骨缺失,并可制成多种缓控释剂型,可提高药效并避免全身用药引起的不良反应。联合抗菌药物与成骨药物制成缓控释制剂并采用局部用药的方式为牙周炎的治疗提供了新的治疗策略。
Periodontitis is the primary cause of loss of adult teeth, the periodontal tissue inflammation and alveolar bone absorption as the main clinical manifestations. Today’s drugs for the treatment of periodontitis are mainly nitroimidazoles, penicillins and tetracyclines, for the control of plaque, to eliminate inflammation; but the lack of allantoin bone can be modified to promote alveolar bone regeneration drugs, thus affecting the clinical efficacy . Finding drugs that promote osteogenesis is particularly important. Many studies have shown that simvastatin, benidipine, naringin and osthole have osteogenesis and can repair alveolar bone loss and can be made into multiple types Controlled-release dosage forms increase efficacy and avoid systemic adverse reactions. Combination of antimicrobial drugs and osteogenesis drugs made of controlled release formulations and the use of local drug treatment for the treatment of periodontitis provides a new treatment strategy.